Skip to main content
Terug
ANIP logo

ANI Pharmaceuticals, Inc.

Datakwaliteit: 100%
ANIP
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
€ 73,31
▼ € 0,61 (-0,83%)
Marktkapitalisatie: 1,65B
Dagbereik
€ 72,92 € 74,43
52-Weeksbereik
€ 56,71 € 99,50
Volume
216.023
50D / 200D Gem.
€ 78,57 / € 80,76
Vorige Slotkoers
€ 73,92

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 21,0 0,3
P/B 3,0 2,9
ROE % 16,2 3,7
Net Margin % 8,9 3,8
Rev Growth 5Y % 42,2 10,0
D/E 0,6 0,2

Koersdoel Analisten

Hold
€ 107,00 +46.0%
Low: € 90,00 High: € 124,00
Forward K/W
8,2
Forward WPA
€ 9,05
WPA Groei (sch.)
+0,0%
Omzet Sch.
1,1 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 13,45
€ 12,71 – € 13,95
1,5 B 2
FY2029 € 12,69
€ 11,99 – € 13,16
1,4 B 2
FY2028 € 12,46
€ 11,78 – € 12,92
1,3 B 3

Belangrijkste Punten

Revenue grew 42,18% annually over 5 years — strong growth
ROE of 16,16% — decent returns on equity
Generating 171,39M in free cash flow
Cash machine — converts 218,79% of earnings into free cash flow
Capital efficient — spends only 1,57% of revenue on capex

Groei

Revenue Growth (5Y)
42,18%
Revenue (1Y)43,78%
Earnings (1Y)N/A
FCF Growth (3Y)30,62%

Kwaliteit

Return on Equity
16,16%
ROIC7,04%
Net Margin8,87%
Op. Margin9,20%

Veiligheid

Debt / Equity
0,60
Current Ratio2,71
Interest Coverage4,05

Waardering

P/E Ratio
21,02
P/B Ratio3,04
EV/EBITDA20,76
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 43,78% Revenue Growth (3Y) 34,71%
Earnings Growth (1Y) N/A Earnings Growth (3Y) 104,24%
Revenue Growth (5Y) 42,18% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 883,37M Net Income (TTM) 78,34M
ROE 16,16% ROA 5,44%
Gross Margin 51,01% Operating Margin 9,20%
Net Margin 8,87% Free Cash Flow (TTM) 171,39M
ROIC 7,04% FCF Growth (3Y) 30,62%
Safety
Debt / Equity 0,60 Current Ratio 2,71
Interest Coverage 4,05 Dividend Yield 0,00%
Valuation
P/E Ratio 21,02 P/B Ratio 3,04
P/S Ratio 1,86 PEG Ratio -0,05
EV/EBITDA 20,76 Dividend Yield 0,00%
Market Cap 1,65B Enterprise Value 1,69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 883,37M 614,38M 486,82M 316,39M 216,14M
Net Income 78,34M -18,52M 18,78M -47,90M -42,60M
EPS (Diluted) 3,32 -1,04 0,94 -3,05 -3,40
Gross Profit 450,64M 364,17M 305,30M 177,60M 115,53M
Operating Income 81,23M 584.000,0 46,97M -35,28M -39,79M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1,44B 1,28B 904,42M 760,09M 771,60M
Total Liabilities 899,65M 855,17M 446,82M 421,55M 412,86M
Shareholders' Equity 540,72M 428,53M 457,60M 338,54M 358,74M
Total Debt 325,20M 624,09M 285,67M 286,52M 287,37M
Cash & Equivalents 285,59M 144,86M 221,12M 48,23M 100,30M
Current Assets 753,12M 527,68M 519,82M 344,26M 321,78M
Current Liabilities 278,11M 193,68M 145,48M 99,44M 87,54M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
#124 of 1052
67

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026